Journal ArticleOPEN ACCESS

Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible?

  • et al.
AIMS Allergy and Immunology (2017) 1(1) 43-49
DOI: 10.3934/allergy.2017.1.43
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Adoptive T-cell immunotherapy is gaining credibility and popularity as a potential tool to 18 cure cancer. Genetic engineering utilization of this therapeutic mode currently comes in the forms of 19 chimeric antigen receptor-and T-cell receptor-engineered T cells. This short review focuses on 20 opportunities to use engineered T cells to treat viral hepatitis-associated hepatocellular carcinoma. 21

Cite

CITATION STYLE

APA

Garssen, J., & Jo, J. (2017). Genetically-engineered T cells to treat viral hepatitis-associated liver cancer: is it possible? AIMS Allergy and Immunology, 1(1), 43–49. https://doi.org/10.3934/allergy.2017.1.43

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free